

Irvin H. Blank Forum II***Modern Genetic Analysis Applied to Cutaneous Cancer***

FRIDAY, MAY 10, 2019

7:30 AM - 8:30 AM


INTERNATIONAL BALLROOM NORTH

7:30 AM**Welcome & Introduction****Cristina de Guzman Strong, PhD**

Dr. de Guzman Strong is an Assistant Professor in the Division of Dermatology and the Center of Pharmacogenomics in the John T. Milliken Department of Medicine at Washington University in St. Louis School of Medicine. She is also a Core Faculty Member in the Center for the Study of Itch at WUSM. She received a B.S. in Biology from Emory University and Ph.D. in Human Genetics from the University of Alabama at Birmingham and completed her post-doctoral training in the Epithelial Biology Section at the National Human Genome Research Institute (NHGRI). Dr. de Guzman Strong has a long-standing interest in the genetics and genomics of the skin with focused studies on the Epidermal Differentiation Complex (EDC) locus. She has been internationally recognized for the molecular discoveries of enhancer-mediated chromatin modeling and genetic macroevolution of the EDC and the translational discoveries for filaggrin stop-gain variants in underserved populations of atopic dermatitis.

**7:35 AM****Carolyn Lee, MD/PhD**, Assistant Professor, Department of Dermatology, Stanford University, Stanford, CA**“Identifying Novel Cancer Genes that Drive Cutaneous Squamous Cell Carcinoma.”**

Her current research is focused on discovering and functionally characterizing new oncogenes and tumor suppressor genes in skin cancer, with particular emphasis on high-risk cutaneous squamous cell carcinoma associated with poor clinical outcomes. As a board-certified dermatologist, Dr. Lee's clinical focus is the management of patients at high risk of developing skin cancer, such as individuals on immune suppression therapy following organ transplant.

**7:55 AM****Kojo Elenitoba-Johnson, MD**, Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

His research focuses on the pathogenesis of human malignant lymphomas, biomarker discovery by genomic and proteomic profiling, and cancer

8:15 AM**Q & A**